Human Amniotic Membrane (hAM) for Stage II Maxillomandibular Osteonecrosis Management
Benefit of Cryopreserved Human Amniotic Membrane (hAM) on Oral Mucosal Healing Among Patients With Stage II Maxillomandibular Osteonecrosis Induced by Antiresorptive and/or Anti-angiogenic Therapies: a Phase II Randomized Trial
Centre Hospitalier Universitaire de Besancon
66 participants
Sep 22, 2023
INTERVENTIONAL
Conditions
Summary
This study aims to demonstrate, during the first standard surgical management of patients with stage II MRONJ, the effect of the implantation of a cryopreserved hAM on the maxillomandibular bone, on the healing of the oral mucosa.
Eligibility
Inclusion Criteria22
- Men and women over the age of 18
- Patient treated in the context of a tumor pathology during which he received treatment with bisphosphonates, Denosumab or anti-angiogenics, and/or, very often, switch of treatment or combination. Current treatment or mention of treatment in patient history
- MRONJ stage II certified clinically and radiologically. Also in the maxilla, stage II MRONJ without bucco-sinus communication after excision of the necrotic bone. Similarly, if a tooth with antral roots must be extracted and creates a bucco-sinus communication, if a MRONJ results, it will be stage II
- Patients with stage II MRONJ of childbearing age with current contraception or patients already postmenopausal
- Signature of the informed consent to participate indicating that the subject has understood the purpose and the procedures required by the study, that he agrees to participate in the study as well as to comply with the requirements and restrictions inherent in this study
- Affiliation to a French social security scheme or beneficiary of such a scheme
- Life expectancy of less than 6 months assessed by oncologists
- Existence of an evolving cervico-facial neoplasia or an evolving oral neoplastic process informed by oncologists
- History of oral and/or cervico-facial radiotherapy
- Allergy to one of these two antibiotics: amoxicillin-clavulanic acid or clindamycin-metronidazole combination
- Patient contraindicated for surgery due to his state of health, with general anesthesia or local anesthesia.
- MRONJ stage I and stage III
- Stage II MRONJ in patients with only osteoporosis
- Patients receiving treatments that may affect bone and/or mucous tissue as well as their metabolism: Patients on long-term corticosteroid therapy or immunosuppressants
- Patients with other diseases that may affect bone and/or mucous tissue as well as their metabolism: Bone diseases (such as brittle bone disease or Osteogenesis imperfecta, primary bone tumors in the maxilla or mandible (osteosarcoma, sarcoma, rhabdomyosarcoma ,…), any other malignant bone tumour; metabolic diseases with bone repercussions (Paget's disease, osteomalacia,…)
- Patients of childbearing age without contraception
- Legal incapacity or limited legal capacity
- Subject unlikely to cooperate in the study and/or low cooperation anticipated by the investigator
- Subject not affiliated to a social security scheme
- Patient under guardianship, curatorship or imprisonment
- Patient who notified his refusal to participate in the research
- Patient who participates in another clinical research
Exclusion Criteria5
- During surgery: Discovery of an interrupting MRONJ with damage to the basilar edge (which corresponds to stage III).
- During surgery: Following a sequestrectomy discovery of spontaneous or ongoing healing.
- During the inclusion period: Patient to benefit from invasive "dental" surgeries directly related to bone exposure and in conjunction with taking risky molecules (factors favoring the occurrence of MRONJ): dental avulsions, curettage apical granulomas or cysts, endodontic treatments, or alveolar bone procedure (regularization of ridges).
- During the inclusion period: Patient with metastases all over the mandible.
- During the inclusion period: State of health of the patient which deteriorates due to his cancer during the inclusion period.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
After conventional/standard treatment, hAM will be applied in a single layer against the bone defect with, if possible, a burial of a few millimeters under the mucous edges. With the idea of apprehending a possible dose effect, the hAM will be adapted to the size of the bone/mucous defect, mesenchymal side against the bone. For closure after hAM grafting : 2 options are possible: Edge-to-edge closure if sufficient mucosal laxity, Edge rapprochement by cross points. If necessary: possible incision of the periosteum to give laxity to the mucosa.
Surgical procedure: Endo-oral approach: * Trimming of the mucous edges if they are necrotic or inflamed (granulation tissue) * For the bone: either simple sequestrectomy (the mobile sequestered bone is grabbed using forceps); either reaming until bleeding is obtained; either resection with the rongeur; either monobloc resection of the entire necrotic fragment with a saw or with a piezzotome (ultrasound); or a combination of different techniques. Rq: the resection of the necrotic bone (according to the practices of the center) will operate until the appearance of an "apparently healthy" bone (bone bleeding, clean appearance of the bone site) * Closure of the mucosa with possible incision of the periosteum to provide laxity: Suture points by points separated in one plane with non-absorbable braided thread of the 3.0 "silk thread" type and round needle.
Locations(5)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05664815